Last deal
Amount
Stage
Date
all rounds
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies999
Anthera Pharmaceuticals
Anthera Pharmaceuticals develops and sells treatments for inflammation-related diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Innocare
InnoCare is a biopharmaceutical company that discovers and develops novel treatments for cancer and autoimmune diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Cotherix
CoTherix develops biopharmaceutical products for chronic diseases.
Sector
Subsector
Location
total rounds
total raised
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical develops therapeutics for rare and ultra-rare diseases.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
M&A Details1
Financials
Funding Rounds1
Number of Funding Rounds
Their latest funding was raised on 01.01.1996. Their latest investor Frazier Healthcare Partners. Their latest round Undisclosed
Co-Investors
Investors1
Number of lead investors
Number of investors
Frazier Healthcare Partners
Frazier Healthcare Partners is a private equity firm that provides growth and venture capital to healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Acquisitions3
DuoCort Pharma acquired by ViroPharma
acquirer
date
type
DuoCort Pharma
DuoCort Pharma has developed Plenadren, an improved glucocorticoid replacement therapy for patients with adrenal insufficiency.
Sector
Subsector
Keywords
Location
Auralis acquired by ViroPharma
acquirer
date
type
Auralis
Auralis develops generic drugs for critical care and pediatrics, targeting niche markets.
Sector
Subsector
Keywords
Location
total rounds
Lev Pharmaceuticals acquired by ViroPharma
acquirer
date
type
price
Lev Pharmaceuticals
Lev Pharmaceuticals is a biopharmaceutical company that develops and sells therapeutic products for inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders1
Claude H. Nash
Dr. Nash brings to Accera more than 20 years of executive management experience in the pharmaceutical and biotechnology industries. Claude Nash is currently the chairman and CEO of Bloodstone Ventures plc. Previously he was the founder, CEO, and chairman of ViroPharma Inc. where he oversaw the development of several antiviral drugs, successfully raised $430M in capital and achieved a $1.2B market capitalization for the company following its Initial Public Offering. Prior to founding ViroPharma, Dr. Nash was Vice President of infectious disease and cancer research at the Schering-Plough Research Institute where he initiated new strategic technologies for drug discovery and advanced three new drugs into development. Throughout his career he has managed the research and development of more than twenty drugs in the areas of infectious diseases, cancer, hypertension and pain. In the past he worked for several large pharmaceutical companies including Sterling-Winthrop, Smith Kline & French, and Eli Lilly. He is currently a director of Adolor, Inc. Dr. Nash earned his Ph.D. degree in microbial genetics and biochemistry from Colorado State University.
current job
organization founded
Claude H. Nash
Employee Profiles98
Jim Nash
Senior vice president technology development and operations
Robert Doody
Assistant director, investor relations
George R. Maurer
Director of Commercial Manufacturing
Robert Pietrusko
Vice President of Global Regulatory Affairs & Quality and Executive Officer